Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024682 | 0.92 | KMT2A (0.65) | KMT2AMEN1ALDH1A1HPGDNPC1 | |
| SCHEMBL4421556 | 0.86 | NPC1 (0.49) | ALDH1A1NPC1RAB9APOLBABCG2 | |
| SCHEMBL10377354 | 0.86 | NPC1 (0.49) | KMT2AMEN1ALDH1A1NPC1RAB9A | |
| SCHEMBL5024711 | 0.85 | NPC1 (0.53) | KMT2AMEN1ALDH1A1HPGDNPC1 | |
| SCHEMBL5026076 | 0.85 | MAPT (0.52) | KMT2AMEN1ALDH1A1HPGDNPC1 | |
| SCHEMBL4422399 | 0.81 | CYP1A2 (0.56) | KMT2AMEN1ALDH1A1HPGDNPC1 | |
| SCHEMBL19305511 | 0.80 | KMT2A (0.85) | KMT2AMEN1ALDH1A1HPGDRAB9A | |
| SCHEMBL4904156 | 0.79 | PDE4D (0.47) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL5026966 | 0.78 | NPC1 (0.52) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL4898316 | 0.78 | CTSL (0.50) | ABCG2ADORA2AADORA1MYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| US-7375109-B2 | Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-05-20 | — | — | US | disclosed |
| EP-1886999-A2 | Bicyclic heteroaromatic compound | N.V. Organon (NL) | 2008-02-13 | — | — | EP | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| CN-1247594-C | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2006-03-29 | — | — | CN | disclosed |
| EP-1427734-B1 | GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
| EP-1427734-A1 | GLYCINE-SUBSTITUTED THIENO 2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | Akzo Nobel N.V. (NL) | 2004-06-16 | — | — | EP | disclosed |
| CN-1462273-A | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2003-12-17 | — | — | CN | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
| EP-1322651-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | Akzo Nobel N.V. (NL) | 2003-07-02 | — | — | EP | disclosed |
| WO-2003020727-A1 | GLYCINE-SUBSTITUTED THIENO [2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL N.V. (NL) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002024703-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS | AKZO NOBEL N.V. (NL) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | KMT2A 1849/4885MEN1 3631/4885ALDH1A1 1372/4885 |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | KMT2A 980/4885MEN1 4277/4885ALDH1A1 1676/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | KMT2A 1414/4885MEN1 2935/4885ALDH1A1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.